在近日举办的"2024香港上市公司发展高峰论坛暨第十一届'港股100强'颁奖典礼"上,备受瞩目的"生物科技榜"结果重磅揭晓。国产创新药龙头企业百济神州(06160.HK)凭借在生物科技领域的领先地位及强大发展潜力,再次蝉联"生物科技榜"榜首。
近年来,随着监管部门鼓励新药研发、以患者获益为核心的政策导向,生物科技行业涌现出不少实力雄厚的优质企业。为了更好地反映行业发展趋势,本次港股100强评选特别推出"生物科技榜",甄选出兼具实力和潜力的生物科技龙头企业。
作为国内生物药品研发的佼佼者,百济神州在该领域独树一帜,引领行业创新发展。公司在临床前及临床阶段研发管线中积累了众多具有全球潜力的在研候选药物,已有3个分子靶点被美国FDA授予突破性疗法认定、5项临床试验被FDA纳入临床计划,体现出百济神州强劲的创新实力。与此同时,公司在大分子生物药、小分子靶向药、免疫单抗偶联药物等多个领域均有部署,充分体现出百济神州的全面创新能力。未来随着更多产品陆续获批上市,百济神州的商业化前景可期。实至名归,百济神州蝉联"生物科技榜"榜首无疑是实力与发展潜力的充分体现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.